Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
GlobalData on MSN4d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP useThe US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a ...
News Medical on MSN3d
New HIV therapy lenacapavir shows high efficacy in Ugandan populationA multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...
A new HIV drug, lenacapavir, appears highly effective against strains circulating in Uganda, according to a study led by ...
The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...
MarketBeat on MSN22h
Gilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application (NDA) for lenacapavir, a long-acting HIV-1 capsid inhibitor, for the prevention of HIV as ...
Gilead is edging closer to an approval for its twice-yearly injectable human immunodeficiency virus-1 (HIV-1) capsid inhibitor, lenacapavir, as a pre-exposure prophylaxis (PrEP) option.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback